JPS59106421A - 利胆剤 - Google Patents
利胆剤Info
- Publication number
- JPS59106421A JPS59106421A JP57216871A JP21687182A JPS59106421A JP S59106421 A JPS59106421 A JP S59106421A JP 57216871 A JP57216871 A JP 57216871A JP 21687182 A JP21687182 A JP 21687182A JP S59106421 A JPS59106421 A JP S59106421A
- Authority
- JP
- Japan
- Prior art keywords
- atractylodine
- sojutsu
- cholagogue
- methanol
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008845 cholagoga Substances 0.000 title abstract 3
- 229940124571 cholagogue Drugs 0.000 title abstract 3
- 239000000731 choleretic agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000284 extract Substances 0.000 abstract description 4
- 241000208838 Asteraceae Species 0.000 abstract description 3
- 239000002934 diuretic Substances 0.000 abstract description 2
- 230000001882 diuretic effect Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000132011 Atractylodes lancea Species 0.000 abstract 1
- 230000007059 acute toxicity Effects 0.000 abstract 1
- 231100000403 acute toxicity Toxicity 0.000 abstract 1
- 230000002279 cholagogic effect Effects 0.000 abstract 1
- 230000003871 intestinal function Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000010898 silica gel chromatography Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001989 choleretic effect Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- 239000013040 bath agent Substances 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GRBKWAXRYIITKG-UHFFFAOYSA-N (1E)-atractylodin Natural products CC=CC#CC#CC=CC1=CC=CO1 GRBKWAXRYIITKG-UHFFFAOYSA-N 0.000 description 1
- GRBKWAXRYIITKG-QFMFQGICSA-N Atractylodin Chemical compound C\C=C\C#CC#C\C=C\C1=CC=CO1 GRBKWAXRYIITKG-QFMFQGICSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940009979 dehydrocholate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220143207 rs779977931 Human genes 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Furan Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57216871A JPS59106421A (ja) | 1982-12-13 | 1982-12-13 | 利胆剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57216871A JPS59106421A (ja) | 1982-12-13 | 1982-12-13 | 利胆剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59106421A true JPS59106421A (ja) | 1984-06-20 |
| JPH0316923B2 JPH0316923B2 (enrdf_load_stackoverflow) | 1991-03-06 |
Family
ID=16695215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57216871A Granted JPS59106421A (ja) | 1982-12-13 | 1982-12-13 | 利胆剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59106421A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016044161A (ja) * | 2014-08-26 | 2016-04-04 | 株式会社ツムラ | アトラクチロジン類の製造方法、及び、コバルト錯体化合物 |
| CN106727487A (zh) * | 2016-12-29 | 2017-05-31 | 泰州中国医药城中医药研究院 | 苍术素在制药中的应用 |
-
1982
- 1982-12-13 JP JP57216871A patent/JPS59106421A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016044161A (ja) * | 2014-08-26 | 2016-04-04 | 株式会社ツムラ | アトラクチロジン類の製造方法、及び、コバルト錯体化合物 |
| CN106727487A (zh) * | 2016-12-29 | 2017-05-31 | 泰州中国医药城中医药研究院 | 苍术素在制药中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0316923B2 (enrdf_load_stackoverflow) | 1991-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS59106421A (ja) | 利胆剤 | |
| JPS61282315A (ja) | 肝不全症治療剤 | |
| KR0156039B1 (ko) | 제조로부터 의약 추출물을 제조하는 방법 및 그 추출물을 함유하는 간장질환의 예방 및 치료용 의약조성물 | |
| US4083994A (en) | Choleretics | |
| NO791704L (no) | Fremangsmaate ved fremstilling av terapeutisk aktive naturlige terpener | |
| US20050118287A1 (en) | Use of a vanilloid as an anti-snoring element | |
| JPH0261921B2 (enrdf_load_stackoverflow) | ||
| JPH01233217A (ja) | 糖尿病治療剤 | |
| WO1994003193A1 (en) | Remedy for biotoxin type bacterial intestinal infectious diseases | |
| JPS6222714A (ja) | 脂質代謝促進剤 | |
| JP3183758B2 (ja) | 血中中性脂肪改善剤及びその製造方法並びにこれを含有する組成物 | |
| JPH0354646B2 (enrdf_load_stackoverflow) | ||
| JPS591684B2 (ja) | 鎮痛剤 | |
| JPH0717507B2 (ja) | 抗血栓剤 | |
| CN101342161A (zh) | 大黄素、芦荟大黄素在制备抗脑缺血损伤药物方面的应用 | |
| CN103768145B (zh) | 治疗强直性脊柱炎的中药制剂 | |
| JP2024515900A (ja) | ピクロシドを含む医薬組成物 | |
| CN104055883B (zh) | 一种治疗急性肝损伤的药物组合物及其应用 | |
| JPS60184017A (ja) | 補気薬 | |
| JPH0733672A (ja) | 動脈硬化抑制剤及びこれを含有する組成物 | |
| JPH01301688A (ja) | トリテルペノイダルサポニン、その製造法ならびにそれを有効成分とする腎臓結石予防剤 | |
| CN116509921A (zh) | 米团花二倍半萜提取物k01在制备治疗脓毒血症的药物中的应用 | |
| JPS6052127B2 (ja) | 利胆剤 | |
| JPH0196120A (ja) | 抗炎症治療剤 | |
| CN103751272A (zh) | 治疗强直性脊柱炎的中药组合物及其提取物 |